5 research outputs found

    Effects of Symbiotic Hydroids on Shell Use by Marine Hermit Crabs in Sarasota, Florida and Roatan, Honduras

    No full text
    (Statement of Responsibility) by Jessica Hickmott(Thesis) Thesis (B.A.) -- New College of Florida, 1999(Electronic Access) RESTRICTED TO NCF STUDENTS, STAFF, FACULTY, AND ON-CAMPUS USE(Bibliography) Includes bibliographical references.(Source of Description) This bibliographic record is available under the Creative Commons CC0 public domain dedication. The New College of Florida, as creator of this bibliographic record, has waived all rights to it worldwide under copyright law, including all related and neighboring rights, to the extent allowed by law.(Local) Faculty Sponsor: Gilchrist, Sandr

    New directions for student services

    No full text
    Publ. comme no 127. fall 2009 de la revue New directions for student servicesIndex.Bibliogr. à la fin des texte

    Human MiniPromoters for ocular-rAAV expression in ON bipolar, cone, corneal, endothelial, Müller glial, and PAX6 cells

    No full text
    Abstract Small and cell-type restricted promoters are important tools for basic and preclinical research, and clinical delivery of gene therapies. In clinical gene therapy, ophthalmic trials have been leading the field, with over 50% of ocular clinical trials using promoters that restrict expression based on cell type. Here, 19 human DNA MiniPromoters were bioinformatically designed for rAAV, tested by neonatal intravenous delivery in mouse, and successful MiniPromoters went on to be tested by intravitreal, subretinal, intrastromal, and/or intravenous delivery in adult mouse. We present promoter development as an overview for each cell type, but only show results in detail for the recommended MiniPromoters: Ple265 and Ple341 ( PCP2 ) ON bipolar, Ple349 ( PDE6H ) cone, Ple253 ( PITX3 ) corneal stroma, Ple32 ( CLDN5 ) endothelial cells of the blood–retina barrier, Ple316 ( NR2E1 ) Müller glia, and Ple331 ( PAX6 ) PAX6 positive. Overall, we present a resource of new, redesigned, and improved MiniPromoters for ocular gene therapy that range in size from 784 to 2484 bp, and from weaker, equal, or stronger in strength relative to the ubiquitous control promoter smCBA. All MiniPromoters will be useful for therapies involving small regulatory RNA and DNA, and proteins ranging from 517 to 1084 amino acids, representing 62.9–90.2% of human proteins
    corecore